| Not Yet Recruiting | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and NCT06281847 | Advesya SAS | Phase 1 / Phase 2 |
| Recruiting | Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT04716452 | Keystone Nano, Inc | Phase 1 |
| Recruiting | A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia NCT07011004 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS NCT06680752 | ARCE Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA NCT06802315 | University of Illinois at Chicago | Phase 2 |
| Withdrawn | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) NCT05854966 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NCT06150040 | Centre Leon Berard | Phase 1 / Phase 2 |
| Recruiting | Master Framework For Relapse or Refractory Acute Myeloid Leukemia NCT06459024 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Recruiting | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS NCT06372717 | Apollo Therapeutics Ltd | Phase 1 |
| Recruiting | Study of REM-422 in Patients With AML or Higher Risk MDS NCT06297941 | Remix Therapeutics | Phase 1 |
| Terminated | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leuk NCT06128044 | Caribou Biosciences, Inc. | Phase 1 |
| Recruiting | Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies NCT05949125 | AvenCell Europe GmbH | Phase 1 |
| Recruiting | Off-the-shelf CD123 CAR-NK for R/R AML NCT06201247 | Peking University People's Hospital | EARLY_Phase 1 |
| Recruiting | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AM NCT06125652 | Xuzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia NCT06017258 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Venetoclax to Augment Epigenetic Modification and Chemotherapy NCT05317403 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mu NCT05546580 | Oryzon Genomics S.A. | Phase 1 |
| Unknown | Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia NCT05574608 | Affiliated Hospital to Academy of Military Medical Sciences | EARLY_Phase 1 |
| Recruiting | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) NCT05190471 | Bio-Path Holdings, Inc. | Phase 1 |
| Recruiting | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332 | University Hospital, Antwerp | Phase 1 |
| Recruiting | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05211570 | AB Science | Phase 1 / Phase 2 |
| Unknown | Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) NCT05488132 | Xuzhou Medical University | Phase 1 / Phase 2 |
| Recruiting | PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML NCT05105152 | Seattle Children's Hospital | Phase 1 |
| Completed | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia NCT04914845 | University of Colorado, Denver | Phase 1 |
| Terminated | CD123 Redirected T Cells for AML in Pediatric Subjects NCT04678336 | University of Pennsylvania | Phase 1 |
| Terminated | Natural Killer-cell Therapy for Acute Myeloid Leukemia NCT04347616 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Lentivirally Redirected CD123 Autologous T Cells in AML NCT03766126 | University of Pennsylvania | Phase 1 |
| Terminated | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML NCT03690154 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 |